Movatterモバイル変換

[0]ホーム
URL:

Jump to content
WikipediaThe Free Encyclopedia
Search

Navacaprant

From Wikipedia, the free encyclopedia
Investigational antidepressant compound
Pharmaceutical compound
Navacaprant
Clinical data
Other namesBTRX-140; CYM-53093; NMRA-140; NMRA-335140
Routes of
administration		Oral[1]
Drug classκ-Opioid receptorantagonist
Identifiers
  • 1-[6-ethyl-8-fluoro-4-methyl-3-(3-methyl-1,2,4-oxadiazol-5-yl)quinolin-2-yl]-N-(oxan-4-yl)piperidin-4-amine
CAS Number
PubChemCID
ChemSpider
UNII
KEGG
Chemical and physical data
FormulaC25H32FN5O2
Molar mass453.562 g·mol−1
3D model (JSmol)
  • CCC1=CC2=C(C(=C(N=C2C(=C1)F)N3CCC(CC3)NC4CCOCC4)C5=NC(=NO5)C)C
  • InChI=1S/C25H32FN5O2/c1-4-17-13-20-15(2)22(25-27-16(3)30-33-25)24(29-23(20)21(26)14-17)31-9-5-18(6-10-31)28-19-7-11-32-12-8-19/h13-14,18-19,28H,4-12H2,1-3H3
  • Key:CQOJHAJWCDJEAT-UHFFFAOYSA-N

Navacaprant (developmental code names includeBTRX-335140,BTRX-140,CYM-53093,NMRA-335140, andNMRA-140) is aselectiveκ-opioid receptor (KOR)antagonist which is under development for the treatment ofmajor depressive disorder andbipolar depression.[2][1][3] It was originated by BlackThorn Therapeutics and is being developed by Neumora Therapeutics.[1] As of February 2025, navacaprant is inphase 3clinical trials for major depressive disorder.[1][4] In January 2025, it was disclosed that navacaprant had failed to show effectiveness for major depressive disorder in a phase 3 trial.[5] Upon this announcement, the stock price of Neumora Therapeutics decreased by 80%.[5]

See also

[edit]

References

[edit]
  1. ^abcd"BTRX 335140 - AdisInsight".adisinsight.springer.com. Retrieved2020-01-25.
  2. ^"BlackThorn Therapeutics Advances Phase 2 Clinical Development for Selective KOR Antagonist, BTRX-140, in Neuropsychiatric Disorders".BlackThorn Therapeutics. Archived fromthe original on 2020-01-25. Retrieved2020-01-25.
  3. ^Guerrero M, Urbano M, Kim EK, Gamo AM, Riley S, Abgaryan L, Leaf N, Van Orden LJ, Brown SJ, Xie JY, Porreca F, Cameron MD, Rosen H, Roberts E (February 2019)."Design and Synthesis of a Novel and Selective Kappa Opioid Receptor (KOR) Antagonist (BTRX-335140)".J. Med. Chem.62 (4):1761–1780.doi:10.1021/acs.jmedchem.8b01679.PMC 6395531.PMID 30707578.
  4. ^Neumora Therapeutics, Inc. (2024-02-20).A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder (Report). clinicaltrials.gov.
  5. ^abTaylor, Nick Paul (2 January 2025)."Neumora stumbles at start of phase 3 depression readout run, sending stock down 80%".Fierce Biotech. Retrieved7 March 2025.

External links

[edit]
μ-opioid
(MOR)
Agonists
(abridged;
full list)
Antagonists
δ-opioid
(DOR)
Agonists
Antagonists
κ-opioid
(KOR)
Agonists
Antagonists
Nociceptin
(NOP)
Agonists
Antagonists
Others
Stub icon

Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Navacaprant&oldid=1333505487"
Categories:
Hidden categories:
[8]ページ先頭
©2009-2026 Movatter.jp